Streptodornase and Streptokinase are enzymes that play a crucial role in the process of fibrinolysis, which is the breakdown of blood clots. These enzymes are produced by certain strains of the bacteria called Streptococcus.
Streptodornase is an extracellular enzyme that degrades DNA. It acts by breaking down the DNA component of the extracellular material that holds the blood clot together. By targeting the DNA, streptodornase weakens the clot structure and helps to dissolve it. This enzyme is particularly effective in breaking down fibrous and organized clots.
Streptokinase, on the other hand, is an enzyme that converts plasminogen, an inactive precursor, to plasmin, which is an active enzyme that degrades fibrin, the protein responsible for clot formation. Plasmin breaks down the fibrin meshwork of the clot, resulting in clot dissolution. Streptokinase has the ability to activate many molecules of plasminogen, amplifying its fibrinolytic effect.
Both streptodornase and streptokinase are commonly used as a combination therapy in the medical field to treat conditions where the formation of blood clots can be detrimental. These conditions can include deep vein thrombosis (DVT), pulmonary embolism, and stroke. Their action is important in restoring blood flow and preventing the development of complications caused by blood vessel blockages.
It is worth noting that the use of streptodornase and streptokinase may have potential side effects, such as allergic reactions, bleeding, or lysis of non-target clots. Therefore, their administration should be carefully monitored by healthcare professionals.
